Small noncoding RNAs, including endogenous antisense RNAs and microRNAs, are involved in many different cellular processes. This issue's Molecular Medicine Select highlights recent work investigating the roles of these RNAs in various aspects of tumorigenesis, suggesting new prognostic, and possibly therapeutic, tools for treating cancer.
miRNAs Promote Metastasis
It turns out that miRNAs may regulate not only cancer cell invasiveness (direct migration and penetration by cancer cells into neighboring tissues) but also tumor metastasis (the process of cancer cells leaving the site of origin and migrating to other locations). Huang et al. (2008) performed a genetic screen to identify miRNAs that induce a nonmetastatic human breast tumor cell line (MCF-7) to invade and migrate in culture assays. Of approximately 450 miRNA-expressing vectors that were tested by transduction into MCF-7 cells, expression of miR-373, miR-520c, and miR-520e induced migration and promoted invasiveness. The miR-373 miRNA has been previously implicated as an oncogene in testicular germ-cell tumors. Three migratory cancer cell lines (breast, prostate, and colon) expressed endogenous miR-373 (but not miR-520); reduced expression of miR-373 (via an antisense oligonucleotide against miR-373) resulted in decreased cell migration. Expression of miR-373 and miR-520c in MCF-7 cells, which are not normally metastatic, induced tumors in remote locations when injected into immunodeficient mice. What are the targets of these miRNAs? Multiple lines of evidence suggest that miR-373 and miR-520c downregulate the expression of CD44, a cell-surface receptor for the glycoprotein hyaluronan. Although CD44 is unlikely to be the only target of these two miRNAs, it is clear that decreased expression of CD44 does contribute to increased tumor cell migration and invasion. Increased expression of CD44 is known to correlate with breast cancer patient survival and to suppress metastasis of prostate and colon cancer cells. Huang et al. demonstrate that increased expression of miR-373 correlates with metastasis of breast tumor cells to lymph node tissue, whereas CD44 expression in the breast tumor cells decreases metastasis to lymph nodes. Together the data suggest that miR-373 and miR-520 may regulate the expression of CD44, a surface protein whose expression is known to decrease metastatic potential. The fact that an anti-miR oligonucleotide reduces tumor cell migration in vitro may open new avenues for cancer treatment. Q. Huang et al. (2008) . Nat. Cell Biol. 10, [202] [203] [204] [205] [206] [207] [208] [209] [210] .And They Suppress Metastasis, Too
Genes that mediate metastasis have been identified and characterized, but less is known about how these genes are downregulated in tumor cells. Tavazoie et al. (2008) now report that expression of six miRNAs is decreased in breast cancer cell lines that are highly metastatic to bone or lung. Importantly, expression of any of these three miRNAs (miR-335, miR-126, or miR-206) decreased the metastatic activity of both tumor cell lines. Metastasis requires cell proliferation, survival, and migration, so the authors investigated at which of these steps the three miRNAs might be operating. Only miR-126 expression suppressed tumor growth, which was attributed to a decrease in proliferation but not apoptosis. Meanwhile, expression of miR-335 and miR-206 reduced tumor cell migration and invasiveness. This suggests that these miRNAs play different roles in blocking metastasis. In tissue samples from breast cancer patients, expression of all three miRNAs is decreased, with the lowest expression correlating with shorter relapse-free intervals and poor survival. What genes do these miRNAs regulate? Expression profiling identified six candidate genes for miR-335 (targets of the other miRNAs were not reported). These genes encode type 1 collagen COLIA1, receptor-type tyrosine protein phosphatase PTPRN2, the c-Mer tyrosine kinase, the phospholipase PLCB1, tenascin C, and the transcription factor SOX4. Reporter and cell-based assays confirmed that SOX4, PTPRN2, c-Mer tyrosine kinase and potentially tenascin C are direct targets of miR-335. Reducing the expression of SOX4 or tenascin C in metastatic breast cancer cells decreased migration, invasive ability, and metastasis. These data suggest that miR-335 regulates metastasis by suppressing metastatic genes, including SOX4 and tenascin C. It will be interesting to learn the targets of the other miRNAs identified in this study, and to see whether this information can be translated into more accurate prognostic assays. S. Tavazoie et al. (2008) . Nature 451, 147-152.
Prognostic miRNA Signatures
Altered expression of miRNAs has been found in many different types of tumors, and miRNA signatures have been reported for chronic lymphocytic leukemia, lung adenocarcinoma, and breast and pancreatic cancer. Now, Yu et al. (2008) demonstrate that a signature of five miRNAs can predict the clinical outcome of non-small-cell lung carcinoma (NSCLC). Using regression analysis, the authors determine that five miRNAs are associated with the survival of NSCLC patients. These include two protective miRNAs (hsa-miR-221 and hsalet-7a) and three ''high-risk'' miRNAs (hsa-miR-137, hsa-miR-372, and hsa-mir-182*). The authors then validated this signature with independent patient samples. Patients with high-risk miRNA signatures had shorter survival times than patients with lowrisk signatures. To demonstrate that these five miRNAs do play a role in cancer, Yu et al. looked at their possible involvement in cancer cell invasiveness (a function not previously associated with miRNAs). Transfection of each of the three high-risk miRNAs increased the invasive ability of a lung cancer cell line that does not normally show this characteristic. In contrast, expression of the protective miRNA, hsa-miR-221, decreased the invasiveness of a high-invasive cell line. However, the protective miRNA hsa-let-7a did not boost the invasiveness of the metastatic lung cancer cell line, perhaps indicating that it may be involved in other aspects of cancer growth or progression. These data have important implications for screening cancer patients, identifying those at high risk and selecting the best chemotherapy regimen. S.-L. Yu et al. (2008) . Cancer Cell 13, 48-57.
Antisense RNA Makes Sense of Silencing
Tumor-suppressor genes are frequently silenced epigenetically in tumor cells. Although DNA methylation is often associated with silencing of tumor-suppressor genes, to date mutations in the DNA methylation machinery of tumors have not been reported. Because noncoding RNAs (including mRNAs and antisense RNAs) present a potential mechanism for gene silencing, Yu et al. (2008) asked if endogenous antisense RNAs (endogenous transcripts with sequences complementary to sense transcripts) lead to silencing of tumor-suppressor genes in tumors. First, they identified antisense RNA transcripts for 21 well-known tumor-suppressor genes. Focusing on one, p15, the authors confirmed the expression of endogenous p15 antisense (p15AS) RNA in two leukemia cell lines and in leukemia patient tissue samples, which displayed increased p15AS expression and decreased p15 expression. Transfection of p15AS downregulates transfected p15 in colon carcinoma cells. The p15AS RNA appears to play a role in the initiation, but not the maintenance, of p15 silencing. Interestingly, no changes in DNA methylation of the p15 promoter were found in p15-transfected cell lines, but alterations in histone methylation were found at the p15 promoter. This suggests that antisense RNA may induce heterochromatin formation at promoters, leading to gene silencing. Introduction of p15AS into embryonic stem cells produces results similar to those seen with cell lines (decreased p15 expression and alterations in histone methylation). However, once the stem cells differentiate into embryoid bodies, the p15 promoter becomes hypermethylated, a result not seen in cell lines, indicating that DNA methylation may be a secondary effect to histone methylation. When the transfected embryonic stem cells were cultured individually, they exhibited increased growth rates. Together, these data suggest that even transient ''doses'' of antisense RNA can induce long-lasting gene silencing of tumor suppressor genes. Antisense RNAs may have potential as diagnostic markers for cancer risk and may be useful targets for developing therapeutics. W. Yu et al. (2008) . Nature 451, [202] [203] [204] [205] [206] Nicole Fox-Tapper mir-206 reduced the ability of breast tumor cells to metastasize to bone (top), compared to a control (mir-122a; bottom). Image courtesy of Joan Massague.
